Global Peanut Allergy Therapeutics Market Strategic Research Report

Scope of the Report

The global Peanut Allergy Therapeutics market size is predicted to grow from US$ 859 million in 2025 to US$ 1,784 million in 2032; it is expected to grow at a CAGR of 11.1% from 2026 to 2032.

Peanut Allergy Therapeutics refer to a range of preventive and treatment approaches designed to address the immune system’s abnormal response triggered by peanut proteins. These therapies include oral immunotherapy (OIT), subcutaneous immunotherapy, and emerging biologics and small molecule drugs, aiming to increase patients’ tolerance to peanuts and reduce the frequency and severity of allergic reactions. As one of the most common and potentially life-threatening food allergies globally affecting both children and adults, peanut allergy significantly impacts patient quality of life and imposes economic burdens on society. With advancements in precision medicine and immune modulation technologies, peanut allergy treatment is evolving from mere avoidance strategies to active immune regulation, driving rapid growth in clinical practice and market demand.

In recent years, rising global awareness of food safety and the expanding population of peanut allergy patients have created significant growth opportunities for the peanut allergy therapeutics market. Governments and regulatory bodies worldwide have progressively improved support policies, facilitating clinical approval and market introduction of immunotherapies and innovative biologics. Advances in medical technologies have enhanced the maturity of oral immunotherapy and personalized treatment regimens, markedly improving patient compliance and safety, thereby accelerating market demand. Multiple biopharmaceutical companies have increased R&D investments, actively developing differentiated products and combination therapies, contributing to a diversified and high-value competitive landscape.Despite vast market potential, the peanut allergy therapeutics sector faces several challenges. Allergic reactions and safety concerns during treatment limit patient acceptance and slow adoption rates. Uneven distribution of medical resources across regions affects treatment accessibility and coverage. Additionally, the high costs and complex management of therapies pose challenges for reimbursement systems and patient affordability. The lack of standardized treatment protocols and regulatory discrepancies further complicate cross-border product launches. Companies must carefully balance innovation breakthroughs with risk management to ensure stable market growth.Downstream demand for peanut allergy therapeutics is moving toward precision and comprehensive care management. With broader adoption of early screening technologies and increased public awareness, more potential patients will receive timely diagnosis and intervention, fostering wider use of immunotherapies. Collaboration among primary care physicians, allergy specialists, and school health programs will strengthen, promoting personalized and long-term treatment management. There is growing demand for safer, more convenient products, while digital health solutions and telemedicine support will become vital tools to enhance adherence and monitor treatment efficacy. Overall, the market is evolving into an integrated ecosystem encompassing diagnosis, therapy, and follow-up care.

This report presents a comprehensive overview of the global Peanut Allergy Therapeutics market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Epinephrine Injection
• Antihistamines
• Oral Immunotherapy
• Other

Segment by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Other

Segment by players, this report covers

• Viatris
• Bayer
• UCB Pharma
• J & J
• Perrigo
• GSK
• Kaleo
• Amneal Pharma
• ALK Abello
• Aimmune Therapeutics
• HUAPONT Pharm
• Allergy Therapeutics
• ASIT Biotech
• Sanofi
• DBV Technologies
• HAL Allergy
• Intrommune Therapeutics

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Peanut Allergy Therapeutics market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in key end-use industries evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact